key: cord-0846577-osbp6eau
authors: Naruse, Keiko
title: Does glycemic control rescue type 2 diabetic patients from COVID‐19‐related deaths?
date: 2020-06-10
journal: J Diabetes Investig
DOI: 10.1111/jdi.13320
sha: f7a7de22b3e10ce2d626a4acaec5cc096d734ce0
doc_id: 846577
cord_uid: osbp6eau

Coronavirus SARS‐CoV‐2, which induced the novel coronavirus disease 2019 (COVID‐19), mainly invades respiratory tract and lung. Severe cases infected by SARS‐CoV‐2 progress to acute respiratory distress syndrome (ARDS), septic shock, and multiple organ dysfunction syndrome (MODS), which leads to death in some cases.

comorbidities who were admitted to Wohan Union Hospital (n=24). They found higher risks of increased severity of pneumonia and mortality with increased inflammatory responses including higher levels of interleukin-6 (IL-6) and coagulation index, D-dimer, than in COVID-19 patients without other comorbidities, including diabetes (n=26) ( Next the authors divided type 2 diabetes group into two further group; well-controlled blood glucose (BG) group (median BG 6.4 mM, glycemic variability ranged from 3.9 to 10.0 mM) and poorly-controlled BG group (median BG 10.9 mM, lowest blood glucose; above or equal 3.9 mM and the highest 2h postprandial glucose; exceed 10.0 mM). They found that the necessity of medical interventions and the mortality risk of patients with COVID-19 was increased by the poor glycemic control in type 2 diabetic patients. On the other hand, well-controlled BG correlated with

This article is protected by copyright. All rights reserved improved survival rates for COVID -19 patients with type 2 diabetes accompanied with higher lymphocyte counts, lower neutrophil counts, and lower serum levels of IL-6, CRP, and lactate dehydrogenase (LDH) (Figure 1 ). The adjusted hazard ratio including comorbidities of all cause of mortality in patients from the well-controlled BG group was 0.13 (P<0.001).

Although it is well known that better glycemic control decreases diabetic complications in type 2 diabetes, the mechanism by which poor glycemic control is associated with the increased mortality risk of diabetic patients with COVID-19 is still unclear. The impairment of immune defense by poor glycemic control will be the probable first-line mechanism. In addition.

Ackermann and colleagues 5 recently published a noteworthy paper that demonstrated distinctive vascular features, consisting of severe endothelial injury associated with the presence of intracellular virus and disrupted cell membranes, in the lungs of patients who died from COVID-19 associated respiratory failure. They found that alveolar capillary microthrombi were 9 times higher in patients with COVID-19 than those in patients who died from influenza. Inherently, the pathogenesis of diabetic complications, both micro-are microvascular complications, is vascular disorder and high glucose impairs the function of vascular endothelial cells.

Poorly-controlled BG-related vascular endothelial dysfunction might be involved in the increased mortality of diabetic patients with COVID-19. Since the sample size of this study was small, further larger scale studies with large scale are expected to explore the mechanism of the aggravation in COVID-19.

COVID-19 patients with diabetes have been reported to have higher mortality compared with non-diabetic COVID-19 patients, however, recent investigations indicated the importance of better glycemic control to avoid the death from COVID-19. To date, multiple variance analysis has shown that there are no significant differences in the mortality of diabetic patients with COVID-19 between different glucose-lowering agents.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Chinese Center for Disease Control and Prevention

Diabetes is a risk factor for the progression and prognosis of COVID-19

Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

This article is protected by copyright. All rights reserved DISCULOSURE The author declares no conflict of interest.